ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026
IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?
Article in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two of the most significant challenges in transplantation medicine are human leukocyte antigen sensitization, which limits access to kidney transplantation for patients with end-stage kidney disease owing to the lack of effective desensitization strategies, and chronic active antibody-mediated rejection (cAMR), a major cause of allograft dysfunction and graft loss following transplantation. Despite its substantial clinical significance, there remains a lack of high-quality evidence and well-established therapeutic algorithms for the management of cAMR, while many patients continue to be excluded from kidney transplantation because of immunological barriers. Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a central role in both innate and adaptive immune responses. Beyond its immunological functions, IL-6 has been implicated in the pathogenesis of a wide range of conditions, including atherosclerotic cardiovascular disease, diabetes mellitus, and various neurological disorders. Consequently, targeting the IL-6/IL-6 receptor signaling pathway has emerged as a promising therapeutic strategy in transplantation medicine, particularly for desensitization protocols and the treatment of cAMR. However, the current evidence base is restricted to studies evaluating tocilizumab and clazakizumab, with clinical benefits remaining inconsistent across studies. Limited evidence is available regarding the desensitization effectiveness of tocilizumab monotherapy. In cAMR, the phase III IMAGINE trial found no improvement in kidney function with clazakizumab despite reduced C-reactive protein. Current evidence does not support a routine IL-6 pathway blockade in cAMR, while further studies are required to prove the potential benefits in desensitization. In this narrative review, we comprehensively examine the role of IL-6 in the pathophysiology of kidney transplantation and critically appraise the available clinical evidence regarding IL-6/IL-6R-targeted therapies for the management of human leukocyte antigen sensitization and cAMR.
Identifiers
42909779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.